

CLAIMS

1. Cutaneous interactive base, characterized in that it essentially comprises biodermal constituents which are cytocompatible with the skin, the said
5 interactive base expressing at least one topical biological activity which is identical to or different from the biological activity of at least one biodermal constituent, and having a composition which gives it a stable topical pharmaceutical form.
- 10 2. Base according to Claim 1, characterized in that it is composed primarily by weight, for example to at least 90%, more preferably 98% by weight, of one or more biodermal constituents which are biomimetic with a component of the skin and whose amount by weight in the
15 said base is different from that of the said component in the skin.
3. Base according to Claim 2, characterized in that its composition is completed with a regulatory biodermal constituent.
- 20 4. Base according to Claim 2, characterized in that it comprises at least two biodermal and biomimetic constituents, the major one of which is a constitutive component of the skin and the minor one of which is a skin nutrient.
- 25 5. Base according to Claim 1, characterized in that at least one biodermal constituent is chosen from the biological, mineral, organic or biochemical species or entities of which the epidermis or the dermis is composed.
- 30 6. Product according to Claim 1, characterized in that at least one biodermal constituent is chosen from skin nutrients.
7. Base according to Claim 1, characterized in that it is a two-phase base and consists of a water-in-
35 oil or oil-in-water emulsion.
8. Cosmetic or body hygiene product, characterized in that it contains at least 98% by weight of a cutaneous interactive base according to Claim 1.

9. Dermotherapeutic product, characterized in that it contains at least 98% by weight of a cutaneous interactive base according to Claim 1.

10. Product according to Claim 8 or 9,
5 characterized in that the cutaneous interactive base represents the entirety of the weight composition of the said product.

11. Use of a combination of biomimetic and bioactive cutaneous constituents to give, solely with
10 the said combination, a stable topical pharmaceutical form for cosmetic or body hygiene use or for dermopharmaceutical use.

12. Use according to Claim 11, characterized in that the stable topical form is a single-phase, two-
15 phase or three-phase form.